Synthorx Inc (THOR) Given $25.50 Consensus Price Target by Brokerages

Synthorx Inc (NASDAQ:THOR) has received a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.

Analysts have set a twelve-month consensus target price of $25.50 for the company and are predicting that the company will post ($0.12) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Synthorx an industry rank of 69 out of 255 based on the ratings given to related companies.

A number of research analysts have weighed in on the stock. HC Wainwright assumed coverage on shares of Synthorx in a report on Wednesday, January 2nd. They issued a “buy” rating and a $30.00 price objective for the company. Jefferies Financial Group assumed coverage on shares of Synthorx in a report on Wednesday, January 2nd. They issued a “buy” rating and a $21.00 price objective for the company.

In other news, major shareholder Ra Capital Healthcare Fund Lp acquired 4,545,455 shares of the business’s stock in a transaction on Tuesday, December 11th. The stock was bought at an average price of $11.00 per share, with a total value of $50,000,005.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Orbimed Advisors Llc acquired 1,363,636 shares of the business’s stock in a transaction on Tuesday, December 11th. The stock was purchased at an average cost of $11.00 per share, with a total value of $14,999,996.00. The disclosure for this purchase can be found here. Insiders acquired 6,454,546 shares of company stock valued at $71,000,006 in the last ninety days. 1.70% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Monashee Investment Management LLC acquired a new stake in shares of Synthorx in the fourth quarter valued at about $435,000. Dean Capital Investments Management LLC acquired a new stake in shares of Synthorx in the fourth quarter valued at about $827,000. Matisse Capital acquired a new stake in shares of Synthorx in the fourth quarter valued at about $956,000. Orbimed Advisors LLC acquired a new stake in shares of Synthorx in the fourth quarter valued at about $92,398,000. Finally, RA Capital Management LLC acquired a new stake in shares of Synthorx in the fourth quarter valued at about $169,014,000. Institutional investors and hedge funds own 0.47% of the company’s stock.

Shares of Synthorx stock opened at $20.95 on Friday. Synthorx has a 1 year low of $11.00 and a 1 year high of $23.53.

About Synthorx

Synthorx, Inc, a biotechnology company, discovers and develops protein therapeutics. The company's lead product candidate is THOR-707, a variant of IL-2 that is in development in various tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company was founded in 2014 and is headquartered in La Jolla, Calif.

Further Reading: Growth Stocks, What They Are, What They Are Not

Get a free copy of the Zacks research report on Synthorx (THOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply